ATE410679T1 - Verfahren zur identifikation von antivirale substanzen - Google Patents

Verfahren zur identifikation von antivirale substanzen

Info

Publication number
ATE410679T1
ATE410679T1 AT02733606T AT02733606T ATE410679T1 AT E410679 T1 ATE410679 T1 AT E410679T1 AT 02733606 T AT02733606 T AT 02733606T AT 02733606 T AT02733606 T AT 02733606T AT E410679 T1 ATE410679 T1 AT E410679T1
Authority
AT
Austria
Prior art keywords
cells
viruses
life cycle
virus
early protein
Prior art date
Application number
AT02733606T
Other languages
English (en)
Inventor
Ronald Brus
Alphonsus Uytdehaag
Govert Schouten
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE410679T1 publication Critical patent/ATE410679T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT02733606T 2001-05-07 2002-05-06 Verfahren zur identifikation von antivirale substanzen ATE410679T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28954101P 2001-05-07 2001-05-07
EP01201657A EP1256803A1 (de) 2001-05-07 2001-05-07 Verfahren zur Identifizierung von antiviralen Verbindungen

Publications (1)

Publication Number Publication Date
ATE410679T1 true ATE410679T1 (de) 2008-10-15

Family

ID=8180262

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02733606T ATE410679T1 (de) 2001-05-07 2002-05-06 Verfahren zur identifikation von antivirale substanzen

Country Status (8)

Country Link
US (1) US7163787B2 (de)
EP (2) EP1256803A1 (de)
AT (1) ATE410679T1 (de)
AU (1) AU2002306089B2 (de)
CA (1) CA2445911C (de)
DK (1) DK1388008T3 (de)
NZ (1) NZ529094A (de)
WO (1) WO2002090982A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
EP1256803A1 (de) 2001-05-07 2002-11-13 Crucell Holland B.V. Verfahren zur Identifizierung von antiviralen Verbindungen
EP2069483A4 (de) * 2006-09-29 2010-10-27 Sanofi Pasteur Biologics Co Rekombinante rhinovirus-vektoren
BRPI0909119A2 (pt) * 2008-03-27 2017-06-13 Sanofi Pasteur Biologics Co vetores recombinantes do rinovírus
HRP20140597T1 (hr) * 2009-07-16 2014-09-12 Crucell Holland B.V. Proizvodnja polio virusa u visokim titrima za proizvodnju cjepiva

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69106353T2 (de) * 1990-04-03 1995-07-13 Southwest Found Biomed Res Immortalisierte primate hepatozyte zellinie.
US6200745B1 (en) 1993-09-09 2001-03-13 The Penn State Research Foundation Vitro assay system using a human cell line for testing the effectiveness of anti-papilloma viral agents
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US5939253A (en) * 1996-04-26 1999-08-17 Diagnostic Hybrids, Inc. Compositions and methods for detecting viral infection
US6218105B1 (en) * 1996-07-19 2001-04-17 Kathleen S. Hall High throughput papilloma virus in vitro infectivity assay
WO1999051776A1 (en) * 1998-04-07 1999-10-14 Southern Research Institute High-throughput method for screening for antiviral activity
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
ES2378272T3 (es) * 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
EP1103610A1 (de) 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
US6682892B2 (en) * 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
EP1256803A1 (de) 2001-05-07 2002-11-13 Crucell Holland B.V. Verfahren zur Identifizierung von antiviralen Verbindungen

Also Published As

Publication number Publication date
CA2445911C (en) 2011-05-24
WO2002090982A1 (en) 2002-11-14
US20040086850A1 (en) 2004-05-06
DK1388008T3 (da) 2009-02-09
EP1256803A1 (de) 2002-11-13
AU2002306089B2 (en) 2007-06-28
EP1388008B1 (de) 2008-10-08
EP1388008A1 (de) 2004-02-11
NZ529094A (en) 2005-07-29
US7163787B2 (en) 2007-01-16
CA2445911A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
DK0988378T4 (da) En fremgangsmåde til in vitro molekylær udvikling af proteinfunktion
DE602004030472D1 (de) Vorrichtung und verfahren zur quantifizierung von mrna aus vollblut mit hohem durchsatz
ATE431853T1 (de) Auf oligonukleotid-modifizierten partikeln basierende bio-strichcodes
ATE416385T1 (de) Verfahren zur quantifizierung der phosphokinaseaktivität auf proteinen
ATE529744T1 (de) Prionproteinliganden und verfahren zu ihrer verwendung
DE60230927D1 (de) Fangverbindungen, ihre entnahme und verfahren zur analysierung des proteoms und von komplexen zusammensetzungen
ATE431854T1 (de) Auf bio-barcodes beruhender nachweis von zielanalyten
Buckley Paleoproteomics: an introduction to the analysis of ancient proteins by soft ionisation mass spectrometry
DE602006006855D1 (de) Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)
DK1680681T3 (da) Fremgangsmåde og apparat til vurdering af polypeptidaggregering
ATE309540T1 (de) Analytisches verfahren unter verwendung von multipelviren-markierung
DE60331857D1 (de) Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
ATE309544T1 (de) Verfahren und vorrichtung zur quantifizierung von lipoprotein-cholesterol hoher dichte
DK1388008T3 (da) Fremgangsmåder til identifikation af antivirale forbindelser
ATE404692T1 (de) Screening-verfahren zur identifizierung von tau- protein modulierenden substanzen.
DK1664793T3 (da) Neurotoksisk aminosyre eller neurotoksisk derivat deraf forbundet med neurologiske lidelser
ATE545460T1 (de) Proteomanalyseverfahren für phosphoryliertes protein
ATE491938T1 (de) Substrat für maldi-tof-ms und massenspektrometrisches verfahren unter verwendung davon
ATE306659T1 (de) Küvette für ein lesegerät zur bestimmung von substanzen mittels der evaneszenzfeldmethode
MXPA01006914A (es) Metodos para identificar combinaciones de entidades como terapeuticas.
ATE392621T1 (de) Verfahren zur quantifizierung von glykiertem protein
ATE290076T1 (de) Ein verfahren zur trennung und reinigung von rna
EP1169641A4 (de) Proteomabbau
ATE449868T1 (de) Methoden, testsätze und kompositionen zur detektion und quantifizierung von zielsequenzen
ATE324178T1 (de) Verfahren zur herstellung eines arrays zur detektion von komponenten aus einer biologischen probe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1388008

Country of ref document: EP